Natural History Study in Patients With LGMDR5/2c
Not yet recruiting
- Conditions
- Gamma-sarcoglycanopathy
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atamyo Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT06210672
- Locations
- 🇫🇷
Hopital Raymond Poincare, Garches, France
🇹🇳National Institute Mongi Ben Hmida of Neurology, Tunis, Tunisia
🇹🇳Hedi Chaker Hospital Child Neurology Department, Sfax, Tunisia
ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Atamyo Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT05973630
- Locations
- 🇺🇸
Child Health Research Institute, Gainsville, Florida, United States
🇫🇷Hopital Trousseau, Paris, France
🇮🇹Ospedale Maggiore Policlinico, Milano, Italy
GNT0006 Gene Therapy Trial in Patients With LGMDR9
Phase 1
Recruiting
- Conditions
- LGMDR9
- Interventions
- Other: GNT0006
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atamyo Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT05224505
- Locations
- 🇫🇷
Institute of Myology Pitié-Salpêtrière Hospital 47 Bd de l'Hôpital, Paris, France
🇬🇧Royal Victoria Infirmary Queen Victoria Road Level 6 Leazes Wing, Newcastle Upon Tyne, United Kingdom
🇩🇰Rigshospitalet, University of Copenhagen Blegdamsvej 9, Copenhagen, Denmark
© Copyright 2025. All Rights Reserved by MedPath